Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)-study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

MALÁSKA Jan STAŠEK Jan DUSKA Frantisek BALIK Martin MACA Jan HRUDA Jan VYMAZAL Tomas KLEMENTOVA Olga ZATLOUKAL Jan GABRHELIK Tomas NOVOTNY Pavel DEMLOVÁ Regina KUBÁTOVÁ Jana UNAR VINKLEROVÁ Jana SVOBODNÍK Adam KRATOCHVÍL Milan KLUČKA Jozef GÁL Roman SINGER Mervyn

Rok publikování 2022
Druh Článek v odborném periodiku
Časopis / Zdroj Trials
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05963-6
Doi http://dx.doi.org/10.1186/s13063-021-05963-6
Klíčová slova COVID-19; Randomised controlled trial; Protocol; ARDS; Dexamethasone; Ventilator-free days
Popis Background: Since December 2019, SARS-CoV-2 virus has infected millions of people worldwide. In patients with COVID-19 pneumonia in need of oxygen therapy or mechanical ventilation, dexamethasone 6 mg per day is currently recommended. However, the dose of 6 mg of dexamethasone is currently being reappraised and may miss important therapeutic potential or may prevent potential deleterious effects of higher doses of corticosteroids. Methods: REMED is a prospective, open-label, randomised controlled trial testing the superiority of dexamethasone 20 mg (dexamethasone 20 mg on days 1-5, followed by dexamethasone 10 mg on days 6-10) vs 6 mg administered once daily intravenously for 10 days in adult patients with moderate or severe ARDS due to confirmed COVID-19. Three hundred participants will be enrolled and followed up for 360 days after randomization. Patients will be randomised in a 1:1 ratio into one of the two treatment arms. The following stratification factors will be applied: age, Charlson Comorbidity Index, CRP levels and trial centre. The primary endpoint is the number of ventilator-free days (VFDs) at 28 days after randomisation. The secondary endpoints are mortality from any cause at 60 days after randomisation; dynamics of the inflammatory marker, change in WHO Clinical Progression Scale at day 14; and adverse events related to corticosteroids and independence at 90 days after randomisation assessed by the Barthel Index. The long-term outcomes of this study are to assess long-term consequences on mortality and quality of life at 180 and 360 days. The study will be conducted in the intensive care units (ICUs) of ten university hospitals in the Czech Republic. Discussion: We aim to compare two different doses of dexamethasone in patients with moderate to severe ARDS undergoing mechanical ventilation regarding efficacy and safety.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.